Niroshana Anandasabapathy
Associate Professor of Dermatology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Niroshana Anandasabapathy is an Associate Professor of Dermatology at Weill Cornell Medical College in the United States. Her research primarily focuses on immune evasion mechanisms of the Vaccinia Virus and the aspects that contribute to successful long-term protective immunity. She is actively involved in advancing the understanding of dermatological immunology through her recent scholarly articles.
Articles (5)
Year:
2026
Year:
2026
Year:
2026
New approaches that generate long-lasting therapeutic responses in patients with therapy-resistant metastatic cancer are urgently needed. To address this challenge, we developed Spot Neoantigens in Metastases (SpotNeoMet), a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to produce neopeptides presented by common HLAs. Using HLA immunopeptidomics, we discovered three novel neopeptides derived from androgen receptor (AR) H875Y, a common metastatic castration-resistant prostate cancer (mCRPC) mutation. We validated these neoantigens as highly immunogenic and then isolated and characterized cognate T-cell receptors (TCR) from healthy donor peripheral blood mononuclear cells. We demonstrated that AR H875Y–specific TCRs are highly specific and kill prostate cancer cells presenting AR neopeptides in vitro and in vivo . Our new pipeline identifies novel immunotherapy targets and potential treatment options for patients with mCRPC. Moreover, SpotNeoMet offers a systematic route to identify “HLA–peptide” pairs and their cognate TCRs across treatment-resistant cancers. Significance: As the emergence of resistance to targeted treatments in patients with metastatic cancer, there is an urgent need for innovative therapeutic approaches for this population. Our study provides a new analytic framework to identify neoantigens from treatment-resistant mutations and a proof-of-concept T cell–based immunotherapy treatment for mCRPC.
Year:
2026
Vaccinia virus is the most successful vaccine in human history and functions as a protective vaccine against smallpox and monkeypox, highlighting the importance of ongoing research into vaccinia due to its genetic similarity to other emergent poxviruses. Moreover, vaccinia’s ability to accommodate large genetic insertions makes it promising for vaccine development and potential therapeutic applications, such as oncolytic agents. Thus, understanding how superior immunity is generated by vaccinia is crucial for designing other effective and safe vaccine strategies. During vaccinia inoculation by scarification, the skin serves as a primary site for the virus–host interaction, with various cell types playing distinct roles. During this process, hematopoietic cells undergo abortive infections, while non-hematopoietic cells support the full viral life cycle. This differential permissiveness to viral replication influences subsequent innate and adaptive immune responses. Dendritic cells (DCs), key immune sentinels in peripheral tissues such as skin, are pivotal in generating T cell memory during vaccinia immunization. DCs residing in the skin capture viral antigens and migrate to the draining lymph nodes (dLN), where they undergo maturation and present processed antigens to T cells. Notably, CD8+ T cells are particularly significant in viral clearance and the establishment of long-term protective immunity. Here, we will discuss vaccinia virus, its continued relevance to public health, and viral strategies permissive to immune escape. We will also discuss key events and populations leading to long-term protective immunity and remaining key gaps.
Year:
2024
Collaborators (21)
Roni Oren
Head of Patient Derived Xenograft (PDX) Service and Human Tissue Samples Bank
Weizmann Institute of Science
Olga Troyanskaya
Professor
Princeton University
Francisco Martínez-Jiménez
Group Leader
Vall d'Hebron Institute of Oncology
David A. Quigley
Assistant Professor
University of California, San Francisco
Eliezer Van Allen
Professor
Harvard University
Raghu Kataru
Senior Research Scientist
Memorial Sloan Kettering Cancer Center
Alexander W. Wyatt
Assistant Professor
The University of British Columbia
Aimee S. Payne
Herbert and Florence Irving Professor and Chair
Columbia University
Shifra Ben-Dor
Senior Staff Scientist
Weizmann Institute of Science
Tamia A. Harris‐Tryon
Vice Chair and Associate Professor
University of Texas Southwestern Medical Center
Sancy Leachman
Oregon Health & Science University
William Shipman
Yale University School of Medicine
Abel Gonzalez-Perez
Co-PI
IRB Barcelona
Theresa Lu
Professor
Weill Cornell Medical College
Shruti Naik
NYU Langone Health
Joaquin Mateo
Group Leader
Vall d´Hebron Institute of Oncology
Masayuki Amagai
Professor and Chair
Keio University School of Medicine
Christoph Ellebrecht
Hospital of the University of Pennsylvania
Anthony Oro
Professor
Stanford University
Yishai Levin
Lab head
Weizmann Institute of Science
Nuria Lopez-Bigas
ICREA Research Professor-Group Leader
Universitat Pompeu Fabra
Make your next move.
Prepare your application
Review drafts before you send them.